ABL1 and acute lymphoblastic leukemia: A nanopore assay was also developed to identify BCR-ABL1 kinase domain (KD) mutations in Philadelphia-positive (Ph +) leukemias: chronic myeloid leukemia (CML) patients with treatment failure and acute lymphoblastic leukemia (ALL) cases at diagnosis (Minervini et al., 2017).